Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy
Status:
Active, not recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to find out if ofatumumab can control CLL or SLL
that is left after chemotherapy or chemoimmunotherapy. The safety of the drug will also be
studied.